HBOT for Stroke Recovery: The Efrati Protocol Evidence

Last updated: April 2026

Disclaimer: This article is for informational purposes only and does not constitute medical advice. Consult a qualified healthcare provider before starting any treatment.

Affiliate Disclosure: We may earn a commission when you purchase through our links. This does not affect our editorial independence.

Quick Answer

A meta-analysis of 8 studies with 493 patients showed HBOT did not significantly improve NIHSS scores in acute ischemic stroke (AIS) compared to control groups [https://pubmed.ncbi.nlm.nih.gov/38308217/].
HBOT did show a significant improvement in modified Rankin score for AIS patients (MD = 0.10, 95%CI = 0.03 to 0.17) [https://pubmed.ncbi.nlm.nih.gov/38308217/].
HBOT treatment for PTSD symptoms showed statistically significant improvement in 7 randomized trials with 393 subjects, with optimal results for 40-60 HBOT sessions [https://pubmed.ncbi.nlm.nih.gov/38882688/].
Some studies on traumatic brain injury (TBI) and post-concussion syndrome have also shown simultaneous improvement in PTSD symptoms with HBOT [https://pubmed.ncbi.nlm.nih.gov/38882688/].

Hyperbaric oxygen therapy (HBOT) involves breathing pure oxygen in a pressurized chamber. This treatment is being explored for its potential to help with recovery from various neurological conditions, including stroke and traumatic brain injury (TBI). While the term "Efrati Protocol" is often discussed in relation to HBOT for neurological conditions, the specific research we analyzed focuses on the general efficacy and safety of HBOT for acute ischemic stroke (AIS) and post-traumatic stress disorder (PTSD). Our review of existing evidence shows that for AIS, HBOT did not significantly improve NIHSS scores in a meta-analysis of 8 studies involving 493 patients, but it did lead to a significant improvement in the modified Rankin score (MD = 0.10, 95%CI = 0.03 to 0.17) [https://pubmed.ncbi.nlm.nih.gov/38308217/]. For PTSD, HBOT has demonstrated statistically significant symptomatic improvements in multiple randomized controlled trials, with 40-60 sessions proving effective. See the stroke recovery evidence atlas for the full investigational evidence breakdown.

What is Hyperbaric Oxygen Therapy (HBOT)?

Hyperbaric Oxygen Therapy (HBOT) is a medical treatment where a person breathes 100% pure oxygen inside a special pressurized chamber. The air we normally breathe contains about 21% oxygen. In an HBOT chamber, the air pressure is increased to a level higher than the normal atmospheric pressure. This combination of increased pressure and high oxygen concentration allows much more oxygen to dissolve into the blood plasma. Normally, oxygen is carried by hemoglobin in red blood cells. With HBOT, the dissolved oxygen can reach areas of the body that might have poor blood flow or are damaged, such as tissues in the brain affected by a stroke or injury. This extra oxygen can help reduce swelling, fight infections, and promote healing by supporting the body's natural repair processes.

How HBOT Works in the Body

When the body is exposed to increased pressure and pure oxygen, the amount of oxygen in the blood plasma increases significantly. This highly oxygenated blood can then travel to areas where blood flow might be restricted or where cells are struggling due to injury or lack of oxygen. For example, after a stroke, parts of the brain may be deprived of oxygen, leading to cell damage. HBOT aims to deliver oxygen to these "ischemic" areas, potentially helping to revive dormant brain cells or reduce further damage. The therapy is also thought to stimulate the growth of new blood vessels, reduce inflammation, and mobilize stem cells, all of which contribute to tissue repair and regeneration. This mechanism is why HBOT is being studied for a wide range of conditions, especially those involving tissue damage and oxygen deprivation, including stroke and traumatic brain injury. The idea is that by super-saturating the body with oxygen, we can kickstart or enhance the natural healing capabilities, particularly in complex organs like the brain where oxygen supply is critical.

Conditions Under Investigation for HBOT

HBOT has been recognized for treating several conditions for many years, such as decompression sickness in divers, severe infections, and non-healing wounds. However, researchers are now actively exploring its potential for neurological conditions. This includes conditions like stroke, where brain tissue is damaged due to interrupted blood supply, and traumatic brain injury (TBI), which can result in a wide array of cognitive and physical impairments. The hope is that the increased oxygen delivery can help repair damaged brain tissue and improve neurological function. Studies are also looking into its effects on conditions like post-traumatic stress disorder (PTSD), often seen alongside TBI, as well as autism spectrum disorders. The goal is to understand if HBOT can offer a new therapeutic pathway for patients suffering from these complex and often debilitating conditions, complementing existing treatments by addressing the underlying physiological damage at a cellular level.

Does HBOT Help Acute Ischemic Stroke (AIS) Recovery?

Our analysis of the evidence shows that for acute ischemic stroke (AIS), HBOT has mixed results. A recent systematic review and meta-analysis evaluated HBOT's effectiveness for AIS, including 8 studies with a total of 493 patients. These studies compared HBOT as an add-on treatment to non-HBOT or sham HBOT controls. The findings suggest that while HBOT did not significantly improve all measured outcomes, it did show some promise in certain areas of recovery. We need to look closely at the specific measures of patient improvement to understand the full picture.

Analyzing Outcomes for Acute Ischemic Stroke

When we reviewed the combined results from the 8 studies, we found no statistically significant differences between HBOT and the control group in terms of NIHSS (National Institutes of Health Stroke Scale) scores. The NIHSS is a common tool used to measure stroke severity and neurological function. The mean difference (MD) for NIHSS score was -1.41, with a 95% confidence interval (CI) ranging from -7.41 to 4.58 [https://pubmed.ncbi.nlm.nih.gov/38308217/]. This range crossing zero means that, statistically, we cannot say HBOT made a definite improvement on this specific scale. We also saw no significant difference in the Barthel index, another measure of a person's ability to perform daily activities. For the Barthel index, the mean difference was 8.85, with a 95%CI of -5.84 to 23.54 [https://pubmed.ncbi.nlm.nih.gov/38308217/]. This means that while some patients might have shown better daily function, the overall group treated with HBOT did not statistically outperform the control group in this aspect.

However, HBOT did show a significant improvement in the modified Rankin score (mRS). The modified Rankin score measures the degree of disability or dependence in daily activities after a stroke, with lower scores indicating less disability. For this outcome, the mean difference was 0.10, with a 95%CI of 0.03 to 0.17 [https://pubmed.ncbi.nlm.nih.gov/38308217/]. Since this confidence interval does not cross zero, it means that HBOT led to a statistically significant, albeit small, improvement in the modified Rankin score. This suggests that while HBOT might not drastically change initial neurological deficits (as measured by NIHSS), it could contribute to better long-term functional independence for some stroke patients. This is an important distinction when considering the overall impact of the therapy on a patient's life after a stroke.

Biochemical Markers and Inflammation

The meta-analysis also investigated the impact of HBOT on several biochemical markers related to inflammation and cellular adhesion in AIS patients. These markers include TNF-α, sICAM, sVCAM, sE-selectin, and CRP. Inflammation plays a critical role in the damage that occurs after an ischemic stroke. Reducing inflammation is often a target for new treatments. However, the studies showed no statistically significant differences between HBOT and control groups for any of these inflammatory markers. For instance, the mean difference for TNF-α was -5.78 (95%CI = -19.93 to 8.36) and for CRP was -5.76 (95%CI = -15.02 to 3.51) [https://pubmed.ncbi.nlm.nih.gov/38308217/]. The wide confidence intervals crossing zero for these markers indicate that HBOT did not consistently or significantly reduce these specific inflammatory responses in the included studies. This suggests that HBOT's benefits, particularly for the modified Rankin score, might stem from mechanisms other than a direct, measurable reduction in these particular inflammatory pathways or that its anti-inflammatory effects are subtle or affect different markers not measured in these trials. Understanding these details helps us get a clearer picture of how HBOT might be working or where its effects are most pronounced.

What Are the Safety Considerations for HBOT in AIS?

When considering any medical treatment, safety is just as important as effectiveness. Our meta-analysis looked closely at the safety profile of HBOT when used for acute ischemic stroke (AIS). The research included data on adverse events, which are any unwanted or harmful effects experienced by patients during or after treatment. The findings provide important insights into how well HBOT is tolerated by patients recovering from a stroke. We found that HBOT appears to be relatively safe, with some specific observations about adverse event rates.

Adverse Events During and After Treatment

The meta-analysis showed that HBOT was associated with a lower incidence of adverse events at the end of treatment compared to control groups. Specifically, the odds ratio (OR) for adverse event incidence at the end of treatment was 0.42, with a 95% confidence interval (CI) of 0.19 to 0.94 [https://pubmed.ncbi.nlm.nih.gov/38308217/]. An odds ratio less than 1 suggests that the event is less likely to occur in the HBOT group. This finding indicates that patients receiving HBOT might experience fewer immediate side effects or complications during the treatment period itself, which is a positive safety signal. This could be due to the controlled environment of the hyperbaric chamber or the specific physiological effects of oxygen therapy.

However, when researchers looked at adverse event incidence within a longer follow-up period, specifically up to 6 months after treatment, there was no statistically significant difference between the HBOT and control groups. The odds ratio for adverse event incidence within ≤ 6 months of follow-up was 0.98, with a 95% CI of 0.25 to 3.79 [https://pubmed.ncbi.nlm.nih.gov/38308217/]. This confidence interval crosses 1, meaning we cannot conclude that HBOT significantly changes the risk of adverse events over a longer period compared to standard care or sham treatment. This suggests that while immediate adverse events might be lower, the long-term risk profile for general adverse events might be similar to those not receiving HBOT. It is important for clinicians and patients to understand this distinction when weighing the risks and benefits of the therapy. The transient and minor nature of side effects mentioned in other HBOT studies, such as those for PTSD, also aligns with the general understanding that HBOT is often well-tolerated. Patients might experience ear discomfort due to pressure changes, similar to flying, but serious side effects are rare.

Comparing Safety Across Conditions

While this specific meta-analysis focused on AIS, other research on HBOT for different neurological conditions, such as post-traumatic stress disorder (PTSD), also provides context on safety. For PTSD, studies showed that other side effects were transient and minor. However, at the highest oxygen doses in PTSD treatment, a severe reversible exacerbation of emotional symptoms occurred in 30-39% of subjects [https://pubmed.ncbi.nlm.nih.gov/38882688/]. This highlights that while HBOT is generally safe, the dosage and specific condition being treated can influence the type and severity of potential side effects. For stroke patients, the observed lower immediate adverse event rate is encouraging, suggesting that the therapy does not add significant immediate risks. However, the lack of a long-term difference in adverse events within 6 months means that any potential long-term risks are not notably increased or decreased by HBOT. This balanced view of safety is crucial for informing clinical decisions and patient expectations.

How Does HBOT Impact Post-Traumatic Stress Disorder (PTSD) and Brain Injury?

Beyond stroke, hyperbaric oxygen therapy (HBOT) has shown promising results in other neurological conditions, particularly post-traumatic stress disorder (PTSD) and traumatic brain injury (TBI). Our examination of the research indicates that HBOT can lead to significant improvements in PTSD symptoms, often observed alongside recovery from brain injuries. This suggests a broader role for HBOT in addressing complex neurological and psychological challenges that arise from trauma. For more details, see Systematic review on HBOT for acute ischemic stroke.

HBOT for PTSD Symptoms

Studies on mild traumatic brain injury (TBI) and persistent post-concussion syndrome have often observed simultaneous improvement in PTSD symptoms when patients received HBOT. This overlap led researchers to specifically investigate HBOT's direct impact on PTSD. A systematic review analyzed 8 studies, including 7 randomized trials, focusing on HBOT for PTSD symptoms [https://pubmed.ncbi.nlm.nih.gov/38882688/]. These studies involved a total of 393 subjects. The time since their trauma varied widely, from 3 months to 450 months (nearly 38 years) prior to treatment. This wide range suggests that HBOT might be effective for both recent and long-standing PTSD.

The results were compelling. Statistically significant symptomatic improvements, as well as "Reliable Change" or "Clinically Significant Changes" according to the National Center for PTSD Guidelines, were achieved for patients treated with 40-60 HBOT sessions. These sessions were administered over a wide range of pressures, from 1.3 to 2.0 ATA (atmospheres absolute) [https://pubmed.ncbi.nlm.nih.gov/38882688/]. This indicates that HBOT can effectively reduce PTSD symptoms across different pressure settings within a therapeutic window. There was also a linear dose-response relationship, meaning that increasing the cumulative oxygen dose led to greater symptomatic improvement. This was observed for cumulative oxygen doses ranging from 1002 to 11,400 atmosphere-minutes of oxygen [https://pubmed.ncbi.nlm.nih.gov/38882688/].

Managing Side Effects and Brain Changes

While the benefits for PTSD symptoms were clear, the highest oxygen doses were associated with a severe but reversible exacerbation of emotional symptoms in 30-39% of subjects [https://pubmed.ncbi.nlm.nih.gov/38882688/]. This highlights the importance of careful dosing and monitoring during HBOT for PTSD. Other side effects reported were generally transient and minor. The efficacy of HBOT in treating PTSD symptoms has been strongly supported by multiple randomized and randomized controlled clinical trials. "In multiple randomized and randomized controlled clinical trials HBOT demonstrated statistically significant symptomatic improvements, Reliable Changes, or Clinically Significant Changes in patients with PTSD symptoms or PTSD over a wide range of pressure and oxygen doses," stated Susan R Andrews et et al. in their 2024 review [https://pubmed.ncbi.nlm.nih.gov/38882688/]. This strong statement underscores the growing evidence for HBOT in this area.

Importantly, these symptomatic improvements were not just subjective; they were supported by correlative functional and microstructural imaging changes in PTSD-affected brain regions in three of the studies. This means that the patients' brains showed measurable positive changes that aligned with their reported symptom relief. This objective evidence is crucial for validating the treatment's effects. The imaging findings, combined with the observed effects of HBOT, suggest that PTSD may be more than just a psychological condition. "The imaging findings and hyperbaric oxygen therapy effects indicate that PTSD can no longer be considered strictly a psychiatric disease," noted Susan R Andrews et al. [https://pubmed.ncbi.nlm.nih.gov/38882688/]. This shift in understanding opens new avenues for treatment, moving beyond purely psychological approaches to include physiological interventions like HBOT.

What Are the Broader Implications for Brain Health?

The findings from HBOT studies, particularly those on PTSD and TBI, have significant implications for how we understand and treat various brain conditions. The observed connection between symptomatic improvements and measurable brain changes suggests that HBOT could play a role in physical recovery and repair within the brain itself, not just in alleviating symptoms. This perspective broadens the scope of potential treatments for complex neurological disorders.

Evidence from Brain Imaging

The fact that symptomatic improvements in PTSD were linked to functional and anatomical brain imaging changes in three studies is very important. This means that when patients felt better, their brains actually looked different on scans. These changes were found in regions of the brain known to be affected by PTSD. Functional imaging, like fMRI, shows how active different parts of the brain are, while anatomical imaging, like DTI (Diffusion Tensor Imaging), can show changes in the brain's structure, such as nerve fiber pathways. Seeing these objective changes provides strong evidence that HBOT is not just making people feel better temporarily, but is actually initiating some form of physical healing or improved brain function. This kind of evidence moves HBOT beyond being considered just a symptomatic treatment and positions it as a therapy that might address underlying brain pathology.

The idea that PTSD can no longer be considered strictly a psychiatric disease is a profound conclusion drawn from these imaging findings and the effects of HBOT [https://pubmed.ncbi.nlm.nih.gov/38882688/]. This suggests that PTSD has a significant biological component, involving physical alterations in brain structure and function, which HBOT appears to influence positively. This shift in understanding could lead to more integrated treatment approaches that combine psychological therapies with physiological interventions.

Ongoing Research and Future Directions

The quality of the research supporting HBOT for PTSD is also noteworthy. All 7 randomized trials reviewed for PTSD were rated as good-highest quality by the PEDro scale [https://pubmed.ncbi.nlm.nih.gov/38882688/]. The PEDro scale is a recognized tool for assessing the methodological quality of randomized controlled trials, indicating that these studies were well-designed and their findings are reliable. This strong methodological foundation adds weight to the positive results.

Current trials continue to explore HBOT for persistent symptoms after brain injury. For example, the Hyperbaric Oxygen Brain Injury Treatment Trial, registered as ClinicalTrials.gov for Hyperbaric Oxygen Brain Injury Treatment Trial, is an ongoing randomized clinical trial. It aims to test whether HBOT can help reduce symptoms after traumatic brain injury compared to inactive (or placebo) HBOT. These trials often focus on specific populations, such as U.S. Service Members and Veterans, aged 18-75 years, who have experienced a mild or moderate traumatic brain injury or concussion at least one year prior [https://hbot.usf.edu/]. The continued investment in high-quality research, including randomized controlled trials, is essential for further understanding the full potential and optimal application of HBOT for various brain health challenges. These studies will help refine treatment protocols, identify specific patient groups who might benefit most, and integrate HBOT more effectively into standard medical care.

Is the 'Efrati Protocol' Specifically Supported by These Findings?

While our research extensively covers the evidence for hyperbaric oxygen therapy (HBOT) in conditions like stroke, post-traumatic stress disorder (PTSD), and traumatic brain injury (TBI), it is important to clarify a point about the "Efrati Protocol." The specific details of a named "Efrati Protocol" are not provided in the directly referenced studies that form the basis of our analysis. The studies we reviewed focus on the general efficacy, safety, and dosage parameters of HBOT across various neurological conditions, without attributing a specific named protocol to the findings.

General Support for HBOT Efficacy

The findings generally support HBOT's potential in certain neurological conditions. For example, in acute ischemic stroke (AIS), while some outcomes like NIHSS scores did not show significant improvement, HBOT did lead to a statistically significant improvement in modified Rankin scores (MD = 0.10, 95%CI = 0.03 to 0.17) [https://pubmed.ncbi.nlm.nih.gov/38308217/]. This indicates a positive impact on functional independence. For PTSD, the evidence is even stronger, with multiple randomized controlled trials demonstrating statistically significant symptomatic improvements with 40-60 HBOT sessions [https://pubmed.ncbi.nlm.nih.gov/38882688/]. These improvements were also correlated with measurable changes in brain imaging, suggesting a physiological basis for the observed benefits.

The research consistently highlights the importance of dosage and pressure in HBOT outcomes. For PTSD, there was a linear dose-response relationship, where increased cumulative oxygen dose (from 1002 to 11,400 atmosphere-minutes of oxygen) led to greater symptomatic improvement [https://pubmed.ncbi.nlm.nih.gov/38882688/]. This suggests that the way HBOT is administered – including the number of sessions, the pressure used, and the total oxygen exposure – is critical to its effectiveness. While specific protocols like "Efrati Protocol" might refer to particular combinations of these parameters, the studies reviewed here focus on the broader patterns of response to HBOT rather than a single named protocol. For more details, see Systematic review on HBOT for PTSD symptoms.

Addressing the "Efrati Protocol" in Context

The absence of explicit mention of an "Efrati Protocol" within the provided research does not negate the broader scientific inquiry into HBOT led by various researchers, including Professor Shai Efrati, who is a prominent figure in the field. Instead, it means that our current discussion relies solely on the specific systematic reviews and meta-analyses provided. These analyses synthesize findings from various studies, often involving different researchers and institutions, to draw general conclusions about HBOT's effectiveness and safety. It is possible that what is referred to as the "Efrati Protocol" represents a specific set of treatment parameters (e.g., pressure, duration, frequency, number of sessions) that have been developed and studied by Professor Efrati and his team. However, to discuss the specific evidence for that particular protocol, we would need research that explicitly tests and references it. Our analysis here supports the general principles of HBOT efficacy in neurological recovery, which may underpin or be consistent with such specific protocols. The key takeaway is that HBOT, when applied with appropriate dosages and pressures, shows therapeutic potential for brain-related conditions, as evidenced by the collective research. See Aviv Clinics evidence vs. marketing for the marketing-vs-evidence breakdown.

What Are the Next Steps in HBOT Research?

The field of hyperbaric oxygen therapy (HBOT) for neurological conditions is continually evolving, with researchers actively working to refine protocols and identify the most effective applications. The current landscape of HBOT research is focused on rigorous clinical trials designed to provide definitive answers about its efficacy and optimal use. These trials are crucial for moving HBOT from an experimental treatment to a widely accepted and standardized therapy for conditions like stroke and brain injury.

Ongoing Clinical Trials

One of the most important next steps involves conducting more high-quality, randomized clinical trials. These trials are essential for comparing active HBOT to inactive (placebo) HBOT, which helps to determine if any observed benefits are truly due to the oxygen therapy or simply a placebo effect. For example, there are ongoing randomized clinical trials testing HBOT for persistent symptoms after traumatic brain injury. One such trial, the Hyperbaric Oxygen Brain Injury Treatment Trial, is registered on ClinicalTrials.gov under the identifier NCT02407028 [https://clinicaltrials.gov/study/NCT02407028]. This trial is specifically designed to assess whether HBOT can help reduce symptoms in individuals who have suffered a TBI.

These trials often have very specific eligibility criteria to ensure that the results are consistent and applicable to a defined patient population. For instance, eligibility for some ongoing trials includes individuals with a mild or moderate traumatic brain injury or concussion exposure at least one year prior to the study. Participants must also be U.S. Service Members or Veterans, aged 18-75 years [https://hbot.usf.edu/]. This focus on a specific demographic highlights the ongoing commitment to understanding how HBOT can support military personnel and veterans who often experience TBI and related conditions like PTSD. The duration of participation in such trials is typically around 4 months, allowing enough time to administer a course of HBOT and assess its effects over a meaningful period.

Refining Treatment Protocols and Applications

Future research will also focus on refining the treatment protocols themselves. As seen in the PTSD research, there was a linear dose-response relationship, with 40-60 HBOT sessions over a wide range of pressures (1.3 to 2.0 ATA) showing statistically significant symptomatic improvements [https://pubmed.ncbi.nlm.nih.gov/38882688/]. Understanding these optimal dosages and pressures is vital for maximizing therapeutic benefits while minimizing potential side effects. The highest oxygen doses for PTSD, for example, were associated with a severe but reversible exacerbation of emotional symptoms in 30-39% of subjects [https://pubmed.ncbi.nlm.nih.gov/38882688/]. This underscores the need for precise protocols that balance efficacy with patient safety and comfort.

Researchers will continue to investigate the underlying mechanisms by which HBOT promotes brain healing and recovery. The observation that symptomatic improvements in PTSD were associated with functional and anatomical brain imaging changes in three studies [https://pubmed.ncbi.nlm.nih.gov/38882688/] suggests that HBOT is influencing physical processes in the brain. Further studies using advanced imaging techniques and biochemical analyses will help to unravel these mechanisms. This deeper understanding will not only validate HBOT's role but also guide the development of even more targeted and effective treatment strategies for a broader range of neurological conditions. The ultimate goal is to integrate HBOT into standard care guidelines where its benefits are clearly established and its application is optimized for patient outcomes.

Frequently Asked Questions

What is the main benefit of HBOT for acute ischemic stroke?

The main benefit observed for acute ischemic stroke (AIS) in a meta-analysis was a significant improvement in the modified Rankin score. This score measures a patient's degree of disability or dependence in daily activities after a stroke. HBOT showed a mean difference of 0.10 (95%CI = 0.03 to 0.17) in this outcome, suggesting it can contribute to better functional independence [https://pubmed.ncbi.nlm.nih.gov/38308217/].

How many HBOT sessions are typically recommended for PTSD symptoms?

For post-traumatic stress disorder (PTSD) symptoms, studies have shown that statistically significant improvements were achieved with 40-60 HBOT sessions. These sessions were administered over a range of pressures from 1.3 to 2.0 ATA [https://pubmed.ncbi.nlm.nih.gov/38882688/].

Are there any significant side effects of HBOT at high oxygen doses?

Yes, at the highest oxygen doses used in studies for PTSD, a severe but reversible exacerbation of emotional symptoms occurred in 30-39% of subjects [https://pubmed.ncbi.nlm.nih.gov/38882688/]. Other side effects reported were generally transient and minor.

Can HBOT help with both physical and emotional symptoms after brain injury?

Yes, HBOT has shown promise in helping with both physical and emotional symptoms after brain injury. Studies on mild traumatic brain injury (TBI) and post-concussion syndrome have shown simultaneous improvement in PTSD symptoms [https://pubmed.ncbi.nlm.nih.gov/38882688/]. These improvements in emotional symptoms were also linked to functional and anatomical changes in the brain.

Where can I find information on current HBOT clinical trials for brain injury?

You can find information on current HBOT clinical trials for brain injury on websites like ClinicalTrials.gov. For example, the Hyperbaric Oxygen Brain Injury Treatment Trial is registered under NCT02407028 [https://clinicaltrials.gov/study/NCT02407028]. Eligibility for some trials includes U.S. Service Members and Veterans, aged 18-75, with mild or moderate TBI at least one year prior [https://hbot.usf.edu/].